A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma.

Louise Ramos Sarah Truong Beibei Zhai Jay Joshi Fariba Ghaidi Michael M Lizardo Taras Shyp Sonia H Y Kung Alireza M Rezakhanlou Htoo Zarni Oo Hans Adomat Stephane Le Bihan Colin Collins Jeffrey Bacha Dennis Brown John Langlands Wang Shen Nada Lallous Poul H Sorensen Mads Daugaard

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our data demonstrates the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bi-functional single-molecule therapeutic strategy.

Keyphrases

single molecule
clinical trial
dna damage
dna repair
histone deacetylase
living cells
randomized controlled trial
electronic health record
oxidative stress
cell therapy
combination therapy
machine learning
artificial intelligence
open label